Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Bristol Myers Squibb & Co (NYSE:BMY) announced results from the Phase 3 CheckMate -76K trial evaluating Opdivo (nivolumab) in melanoma patients.
- Opdivo as a single agent in the adjuvant setting in patients with completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo.
- Related: Bristol Myers' Deucravacitinib Scores FDA Approval For Plaque Psoriasis.
- No new safety signals were observed at the time of the analysis.
- CheckMate -76K is part of BMS' development program studying Opdivo and Opdivo-based combinations in earlier stages of cancer, which currently spans seven tumor types.
- The company will complete a full evaluation of the CheckMate -76K data and looks forward to sharing the results at an upcoming medical conference.
- Price Action: BMY shares are up 1.37% at $71.44 on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!